SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

2/14/24 4:26:22 PM ET

$IMGN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMGN alert in real time by email

SC 13G/A 1 tm245846d22_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 6)

ImmunoGen, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

45253H101

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45253H101

1	Name of Reporting Person Redmile Group, LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization Delaware
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 16,423,922 ⁽¹⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 16,423,922 ⁽¹⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 16,423,922 ⁽¹⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	Percent of Class Represented by Amount in Row (9) 5.9%⁽²⁾
12	Type of Reporting Person (See Instructions) IA, OO

⁽¹⁾ Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 16,423,922 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

⁽²⁾ Percentage based on 279,354,016 shares of Common Stock outstanding as of December 29, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed with the SEC on January 31, 2024 (the “Form 8-K”).

CUSIP No. 45253H101

1	Name of Reporting Person Jeremy C. Green
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization United Kingdom
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 16,423,922 ⁽³⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 16,423,922 ⁽³⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 16,423,922 ⁽³⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	Percent of Class Represented by Amount in Row (9) 5.9%⁽⁴⁾
12	Type of Reporting Person (See Instructions) IN, HC

⁽³⁾ Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 16,423,922 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

⁽⁴⁾Percentage based on 279,354,016 shares of Common Stock outstanding as of December 29, 2023, as reported by the Issuer in the Form 8-K.

Item 1.

(a)

Name of Issuer

ImmunoGen, Inc.

(b)

Address of Issuer’s Principal Executive Offices

830 Winter Street

Waltham, MA 02451

Item 2.

(a)

Names of Persons Filing

Redmile Group, LLC
Jeremy C. Green

(b)

Address of Principal Business office or, if None, Residence

Redmile Group, LLC
One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001

(c)

Citizenship

Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom

(d)

Title of Class of Securities

Common Stock, $0.01 par value

(e)

CUSIP Number

45253H101

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)

Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

Item 4.

Ownership.

(a)

Amount beneficially owned:

Redmile Group, LLC – 16,423,922 *
Jeremy C. Green – 16,423,922 *

(b)

Percent of class:

Redmile Group, LLC – 5.9%**
Jeremy C. Green – 5.9%**

(c)

Number of shares as to which Redmile Group, LLC has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

16,423,922 *

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

16,423,922 *

Number of shares as to which Jeremy C. Green has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

16,423,922 *

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

16,423,922 *

Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 16,423,922 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

Percentage based on 279,354,016 shares of Common Stock outstanding as of December 29, 2023, as reported by the Issuer in the Form 8-K

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

See the response to Item 4.

Item 8.

Identification and Classification of Members of the Group.

N/A.

Item 9.

Notice of Dissolution of Group.

N/A.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2024

	Redmile Group, LLC

	By:		/s/ Jeremy C. Green
			Name: Jeremy C. Green Title: Managing Member

			/s/ Jeremy C. Green
			Jeremy C. Green

Get the next $IMGN alert in real time by email

Recent Analyst Ratings for

$IMGN

Date	Price Target	Rating	Analyst
12/1/2023	$25.00 → $31.00	Buy → Neutral	Guggenheim
11/20/2023	$17.00	Neutral	Goldman
11/9/2023	$25.00	Buy	Deutsche Bank
10/6/2023	$16.00	Perform	Oppenheimer
5/3/2023	$6.00 → $16.00	Neutral → Overweight	Piper Sandler
11/21/2022	$10.00	Buy	Truist
9/9/2022	$8.00	Overweight	Barclays
3/21/2022	$9.00 → $6.00	Outperform → Sector Perform	RBC Capital Mkts

More analyst ratings

SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

2/14/24 4:26:22 PM ET

$IMGN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMGN alert in real time by email

SC 13G/A 1 tm245846d22_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 6)

ImmunoGen, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

45253H101

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

CUSIP No. 45253H101

1	Name of Reporting Person Redmile Group, LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization Delaware
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 16,423,922 ⁽¹⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 16,423,922 ⁽¹⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 16,423,922 ⁽¹⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	Percent of Class Represented by Amount in Row (9) 5.9%⁽²⁾
12	Type of Reporting Person (See Instructions) IA, OO

CUSIP No. 45253H101

1	Name of Reporting Person Jeremy C. Green
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization United Kingdom
number of shares beneficially owned by each reporting person with		5	Sole Voting Power 0
		6	Shared Voting Power 16,423,922 ⁽³⁾
		7	Sole Dispositive Power 0
		8	Shared Dispositive Power 16,423,922 ⁽³⁾
9	Aggregate Amount Beneficially Owned by Each Reporting Person 16,423,922 ⁽³⁾
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	Percent of Class Represented by Amount in Row (9) 5.9%⁽⁴⁾
12	Type of Reporting Person (See Instructions) IN, HC

⁽⁴⁾Percentage based on 279,354,016 shares of Common Stock outstanding as of December 29, 2023, as reported by the Issuer in the Form 8-K.

Item 1.

(a)

Name of Issuer

ImmunoGen, Inc.

(b)

Address of Issuer’s Principal Executive Offices

830 Winter Street

Waltham, MA 02451

Item 2.

(a)

Names of Persons Filing

Redmile Group, LLC
Jeremy C. Green

(b)

Address of Principal Business office or, if None, Residence

Redmile Group, LLC
One Letterman Drive
Building D, Suite D3-300
The Presidio of San Francisco
San Francisco, California 94129

Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001

(c)

Citizenship

Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom

(d)

Title of Class of Securities

Common Stock, $0.01 par value

(e)

CUSIP Number

45253H101

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)

Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

Item 4.

Ownership.

(a)

Amount beneficially owned:

Redmile Group, LLC – 16,423,922 *
Jeremy C. Green – 16,423,922 *

(b)

Percent of class:

Redmile Group, LLC – 5.9%**
Jeremy C. Green – 5.9%**

(c)

Number of shares as to which Redmile Group, LLC has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

16,423,922 *

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

16,423,922 *

Number of shares as to which Jeremy C. Green has:

(i)

Sole power to vote or to direct the vote:

(ii)

Shared power to vote or to direct the vote:

16,423,922 *

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

16,423,922 *

Percentage based on 279,354,016 shares of Common Stock outstanding as of December 29, 2023, as reported by the Issuer in the Form 8-K

Item 5.

Ownership of Five Percent or Less of a Class.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

See the response to Item 4.

Item 8.

Identification and Classification of Members of the Group.

N/A.

Item 9.

Notice of Dissolution of Group.

N/A.

Item 10.

Certifications.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2024

	Redmile Group, LLC

	By:		/s/ Jeremy C. Green
			Name: Jeremy C. Green Title: Managing Member

			/s/ Jeremy C. Green
			Jeremy C. Green

Get the next $IMGN alert in real time by email

Recent Analyst Ratings for

$IMGN

Date	Price Target	Rating	Analyst
12/1/2023	$25.00 → $31.00	Buy → Neutral	Guggenheim
11/20/2023	$17.00	Neutral	Goldman
11/9/2023	$25.00	Buy	Deutsche Bank
10/6/2023	$16.00	Perform	Oppenheimer
5/3/2023	$6.00 → $16.00	Neutral → Overweight	Piper Sandler
11/21/2022	$10.00	Buy	Truist
9/9/2022	$8.00	Overweight	Barclays
3/21/2022	$9.00 → $6.00	Outperform → Sector Perform	RBC Capital Mkts

More analyst ratings

SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $IMGN

SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $IMGN

$IMGN SEC Filings

SEC Form 15-12G filed by ImmunoGen Inc.

SEC Form S-8 POS filed by ImmunoGen Inc.

SEC Form S-8 POS filed by ImmunoGen Inc.

$IMGN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Mitchell Dean J returned 103,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

SEC Form 4 filed by Peterson Kristine

Thackray Helen M. returned 3,074 shares to the company, closing all direct ownership in the company (SEC Form 4)

$IMGN Leadership Updates

Live Leadership Updates

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Seaport Therapeutics Names Lauren White as Chief Financial Officer

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$IMGN FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

March 26, 2024 - FDA Roundup: March 26, 2024

FDA Approval for ELAHERE issued to IMMUNOGEN INC

FDA Approval for ELAHERE issued to IMMUNOGEN INC

$IMGN Press Releases

Fastest customizable press release news feed in the world

Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Seaport Therapeutics Names Lauren White as Chief Financial Officer

$IMGN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ImmunoGen downgraded by Guggenheim with a new price target

Goldman initiated coverage on ImmunoGen with a new price target

Deutsche Bank initiated coverage on ImmunoGen with a new price target

$IMGN Financials

Live finance-specific insights

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results

$IMGN Large Ownership Changes

This live feed shows all institutional transactions in real time.